glp-1 drug updates Medicare is about to cover drugs for weight loss. Here's what to know While many patients are seeing

Emerging preclinical evidence suggests GLP-1 may influence neuronal survival, synaptic plasticity, and neuroinflammationprocesses that are disrupted in neurodegenerative conditions

A notable RCT is the pioglitazone in early PD trial, which failed to demonstrate the possibility of pioglitazone delaying disease progression in early-stage PD patients [38]

A common factor in metabolic diseases like diabetes, inflammation is a key component of the body's natural immune defence mechanism to protect itself

A significant concern is that the most common adverse effects of GLP-1 agonistsnausea, vomiting, diarrhea, and abdominal painoverlap substantially with Crohn's disease symptoms

Advanced brain imaging techniques are helping them understand the results more clearly

Frontiers In Cardiovascular Medicine 9:966968 Gibb AA, Murray EK, Eaton DM, Huynh AT, Tomar D, Garbincius JF, Kolmetzky DW, Berretta RM, Wallner M, Houser SR, Elrod JW (2021) Molecular signature of HFpEF: systems biology in a cardiac-centric large animal model